Calidi Biotherapeutics (CLDI) Change in Accured Expenses (2022 - 2025)
Calidi Biotherapeutics (CLDI) posted quarterly Change in Accured Expenses of -$808000.0 for Q4 2025, down 42.0% year-over-year from -$1.4 million in Q4 2024, and down 406.06% quarter-over-quarter from $264000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Change in Accured Expenses (2022 - 2025) Analysis & Trends
Calidi Biotherapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at -$808000.0 for Q4 2025.
- In Q4 2025, Change in Accured Expenses fell 42.0% year-over-year to -$808000.0; the TTM figure through Dec 2025 stood at -$2.0 million (down 7.5% YoY), while the FY2025 annual figure was -$2.0 million, down 7.5% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at -$808000.0, down from $264000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.0 million in Q3 2022, with the low at -$1.7 million in Q1 2025.
- The 4-year median for Change in Accured Expenses is -$106160.5 (2022), against an average of -$49812.5.
- The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses soared 5509.07% in 2023, then sank 334.79% in 2025.
- Calidi Biotherapeutics' Change in Accured Expenses stood at -$223000.0 in 2022, then soared by 359.19% to $578000.0 in 2023, then tumbled by 198.44% to -$569000.0 in 2024, then plunged by 42.0% to -$808000.0 in 2025.
- Business Quant data shows CLDI's Change in Accured Expenses at -$808000.0 in Q4 2025, $264000.0 in Q3 2025, and $238000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -808,000.00 |
| Dec 31, 2025 | -808,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Mar 31, 2025 | -1.69 Mn |
| Mar 31, 2025 | -1.69 Mn |
| Dec 31, 2024 | -569,000.00 |
| Dec 31, 2024 | -569,000.00 |
| Sep 30, 2024 | -190,000.00 |
| Sep 30, 2024 | -190,000.00 |
| Jun 30, 2024 | -707,000.00 |
| Jun 30, 2024 | -707,000.00 |
| Mar 31, 2024 | -388,000.00 |
| Mar 31, 2024 | -388,000.00 |
| Dec 31, 2023 | 578,000.00 |
| Dec 31, 2023 | 578,000.00 |
| Sep 30, 2023 | -791,000.00 |
| Sep 30, 2023 | -791,000.00 |